Spots Global Cancer Trial Database for Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Official Title: A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Study ID: NCT05379985
Interventions
Study Description
Brief Summary: Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Detailed Description: This is a Phase 1/1b, multicenter open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), and clinical activity of escalating doses of RMC-6236 in adult patients with advanced solid tumors harboring specific RAS mutations, and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose \[RP2D\] within investigated patient population groups. RMC-6236 is a potent, orally bioavailable RAS-MULTI(ON) inhibitor, selective for the active RAS(ON) form of both wild type and mutant variants of the canonical RAS isoforms (HRAS, NRAS, and KRAS).
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UC Irvine/Chao Family Comprehensive Cancer Center, Orange, California, United States
UCLA, Santa Monica, California, United States
Johns Hopkins University, Baltimore, Maryland, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Columbia University, New York, New York, United States
Christ Hospital Cancer Center, Cincinnati, Ohio, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
University of Texas at Austin, Austin, Texas, United States
Mary Crowley Cancer Research, Dallas, Texas, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Next Oncology, San Antonio, Texas, United States
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Next Oncology Virginia, Fairfax, Virginia, United States
Contact Details
Name: Revolution Medicines, Inc.
Affiliation: Revolution Medicines, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
